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Burden of maternal and fetal
outcomes among pregnant
cancer survivors during delivery
hospitalizations in the United
States
Muni Rubens1, Venkataraghavan Ramamoorthy2, Anshul Saxena2, Peter McGranaghan1,
Sandeep Appunni3, Md Ashfaq Ahmed2, Zhenwei Zhang2, Shelbie Burchfield4, Raees Tonse1,
Emir Veledar2 & Rupesh Kotecha1,4,5*
Existing studies on pregnancy-related outcomes among cancer survivors are limited by sample size or
specificity of the cancer type. This study estimated the burden of adverse maternal and fetal outcomes
among pregnant cancer survivors using a national database. This study was a retrospective analysis of
National Inpatient Sample collected during 2010–2014. Multivariate regression models were used to
calculate odds ratios for maternal and fetal outcomes. The study included a weighted sample of 64,506
pregnant cancer survivors and 18,687,217 pregnant women without cancer. Pregnant cancer survivors
had significantly higher odds for death during delivery hospitalization, compared to pregnant women
without cancer (58 versus 5 deaths per 100,000 pregnancies). They also had higher odds of severe
maternal morbidity (aOR 2.00 [95% CI 1.66–2.41]), cesarean section (aOR 1.27 [95% CI 1.19–1.37]),
labor induction (aOR 1.17 [95% CI 1.07–1.29]), pre-eclampsia (aOR 1.18 [95% CI 1.02–1.36]), preterm
labor (aOR 1.55 [95% CI 1.36–1.76]), chorioamnionitis (aOR 1.45 [95% CI 1.15–1.82]), postpartum
infection (aOR 1.68 [95% CI 1.21–2.33]), venous thromboembolism (aOR 3.62 [95% CI 2.69–4.88]), and
decreased fetal movements (aOR 1.67 [95% CI 1.13–2.46]). This study showed that pregnancy among
cancer survivors constitutes a high-risk condition requiring advanced care and collective efforts from
multiple subspecialties.
Advances in cancer treatment have significantly increased survival rates among women in the reproductive age
group. Complications associated with cancer and its treatment can have significant adverse effects on maternal
and fetal outcomes during subsequent pregnancies1. A study using the Scottish Cancer Registry showed that
obstetrical complications such as post-partum hemorrhage, preterm delivery, cesarean section and assisted delivery were significantly higher among women with cancer compared to non-cancer p
 atients2. Similarly, another
study using the North Carolina Central Cancer Registry showed that the risk for preterm birth, low birth weight,
and cesarean delivery were significantly higher among women with c ancer3. In addition to these adverse associations, the symptoms of cancer often resemble normal physiological changes in pregnancy, leading to difficulty
in diagnosing cancer during pregnancy4–6. The effects of these changes increase both maternal and fetal adverse
outcomes among pregnant cancer survivors7. The fetus is as vulnerable as the pregnant woman to the adverse
effects of cancer and antineoplastic treatment. In spite of scientific advancements and newer cancer treatments
with minimal adverse effects to the growing f etus8,9, adverse outcomes such as growth retardation and preterm
deliveries are still fairly common10. Given these adverse maternal and fetal outcomes, there is a clear need for
studies to estimate the national burden of these problems to better define the scope of the issue.
Most of the previously published studies are either small scale, with limited sample sizes, or limited to specific
types of c ancers11–16, and large, nationally representative studies are scarce. Hence, the objective of this study
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was to determine nationally representative estimates of maternal and fetal outcomes among cancer survivors in
the US, using the National Inpatient Sample (NIS), the largest database of hospitalization records in the country.

Methods

This study was a cross-sectional analysis of National Inpatient Sample (NIS) data collected during the years
2010–2014. NIS was developed by the Agency for Healthcare Research and Quality (AHRQ) as a part of the
Healthcare Cost and Utilization Project (HCUP). NIS is the largest all payer inpatient database and includes
stratified sample of discharge data from 20% of all community hospitals within the US. Stratification is based on
hospital location, bed size, hospital region, teaching status, and ownership. The NIS includes 20% of stratified
sample of discharges from all US community hospitals located in the states participating in HCUP and covers
more than 97% of the US population. HCUP redesigned the NIS data in 2012 to improve national estimates. It
was changed to sample discharge records from all HCUP-participating hospitals, rather than a sample of hospitals
from which all discharges were retained. Annually, more than 35 million weighted hospitalizations are captured
by the NIS. Any hospital was considered a teaching hospital when it had a residency program approved by the
Accreditation Council for Graduate Medical Education, was included in the Council of Teaching Hospitals, or
had a resident to bed ratio of 0.25 or higher. Appropriate sample weights were used to obtain national estimates.
The weights were calculated based on stratifying the hospitals by the following variables: census division, urban/
rural location, teaching status, bed size, and ownership. The weights were estimated for each stratum, by calculating the ratio of overall discharges to the number of NIS discharges in those stratums. International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes were used for
reporting diagnoses and procedures during hospitalizations. Using previously validated m
 ethods17, we used
ICD-9-CM codes for identifying women who underwent delivery during hospitalizations irrespective of their
age. We used the ICD-9-CM diagnosis and procedure codes and diagnosis-related group (DRG) codes described
in Supplementary Table 1 for identifying delivery hospitalizations. Within this sample, we identified cancer
survivors using Clinical Classifications Software (CCS) codes 11-43, which indicate malignancies18. However,
we could not identify whether patients were having concurrent malignancies or cancer treatments while being
pregnant, or whether they were childhood cancer survivors. We followed the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guidelines for reporting our findings.

Patient and hospital characteristics. A number of demographic variables such as age, race, insurance

coverage, and income were extracted from the database. ICD-9-CM diagnosis and procedure codes were used
for identifying Elixhauser comorbidity index19,20, multiple pregnancies, previous cesarean section, pre-existing
diabetes, hypertension, chronic renal disease, alcohol and substance use, depression, and psychiatric disorders
(Supplementary Table 1). Hospital characteristics such as hospital location, region, bed size, and teaching status
were also extracted from this database.

Maternal and fetal outcomes. We used ICD-9 codes to identify adverse maternal and fetal outcomes
(Supplementary Table 2). We estimated overall maternal morbidity using the maternal morbidity composite
outcome developed by the Centers for Disease Control and Prevention21,22. We also identified adverse maternal outcomes, such as maternal death, cesarean delivery, induction of labor, length of stay, pregnancy-related
hypertension, eclampsia, antepartum and postpartum hemorrhage, gestational diabetes, preterm labor, premature rupture of membrane, and chorioamnionitis, and fetal outcomes such as poor fetal growth, excessive fetal
growth, fetal distress, fetal abnormalities, decreased fetal movements, and stillbirth. All mothers with multiple births were considered as single delivery hospitalizations. In this study, maternal mortality was defined as
death during delivery hospitalizations due to any cause. The study was exempt from institutional review board
approval as it uses previously collected deidentified data stored in NIS.
Statistical analyses. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary,

NC) using procedures that accounted for complex sampling design and clustering of the N
 IS23. To account for
the redesigning of NIS data in 2012, we used trend weight (TRENDWT) for the years 2010 to 2011 and regular
discharge weight (DISCWT) for the years 2012 to 2014. Descriptive statistics were calculated to understand
demographics, hospital characteristics, and maternal and fetal outcomes, and were reported in terms of mean,
percentages and standard errors. Rao-Scott χ2 tests were used for categorical variables, while Mann–Whitney U
tests were used for continuous variables. Multivariate regression models were used to calculate odds ratios (ORs)
and 95% confidence intervals (CIs) for all binary maternal and fetal outcomes. Regression models also included
maternal age, race, median household income, Elixhauser comorbidity index, hospital region, hospital location
(urban or rural), hospital teaching status and year. Variables which were significant at P < 0.01 in the bivariate
analysis were included in the final model. Percent of missing data was small, and since data were not missing
completely at random, we used the NOMCAR option during the regression analysis. All reported estimates are
weighted estimates. Statistical significance was set at P < 0.05 and all tests were 2 sided.

Ethics approval and consent to participate. The study was reviewed by the Miami Cancer Institute’s

Institutional Review Board, which exempted the study from institutional review board approval and waived the
requirement for informed consent because it uses previously collected deidentified data stored in NIS. We followed the Strengthening the Reporting of Observational Studies in Epidemiology guidelines for reporting our
findings.
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Characteristics

Cancer survivors

Without cancer

Unweighted sample

13,109

3,801,606

Weighted sample

64,506

18,687,217

Age in years, mean (SE)

30.5 (0.08)

28.0 (0.03)

63.5% (0.97)

52.9% (0.52)

Race, % (SE)

P value

< 0.001
< 0.001

White
Black

12.3% (0.53)

14.5% (0.30)

Hispanic

16.2% (0.83)

21.6% (0.47)

Asian or Pacific Islander

4.1% (0.27)

5.4% (0.20)

Native American

0.45% (0.07)

0.80% (0.05)

Other

3.5% (0.22)

4.8% (0.15)

1.8% (0.12)

0.7% (0.04)

Insurance type, % (SE)

< 0.001

Medicare
Medicaid

35.9% (0.91)

43.9% (0.45)

Private insurance

57.5% (0.95)

49.8% (0.48)

Self-pay

1.8% (0.16)

2.6% (0.10)

No chargea

0.13% (0.03)

0.12% (0.03)

Otherb

2.9% (0.17)

2.9% (0.08)

24.2% (0.73)

27.7% (0.47)

Median household income for patient’s zip code, % (SE)
Quartile 1

< 0.001

Quartile 2

22.7% (0.48)

25.0% (0.32)

Quartile 3

25.4% (0.50)

25.2% (0.30)

Quartile 4

27.7% (0.79)

22.1% (0.57)

Elixhauser comorbidity index ≥ 4, % (SE)

3.1% (0.16)

0.70% (0.01)

< 0.001

Multiple birth, % (SE)

2.8% (0.16)

1.8% (0.02)

< 0.001

Previous cesarean delivery, % (SE)

18.9% (0.36)

17.2% (0.05)

< 0.001

Preexisting diabetes mellitus, % (SE)

1.6% (0.11)

1.0% (0.01)

< 0.001

Chronic renal disease, % (SE)

0.60% (0.07)

0.28% (0.01)

< 0.001

Preexisting hypertension, % (SE)

4.0% (0.18)

2.3% (0.02)

< 0.001

Depression, % (SE)

4.8% (0.20)

2.3% (0.04)

< 0.001

Alcohol or substance abuse, % (SE)

3.2% (0.20)

1.8% (0.03)

< 0.001
< 0.001

Psychiatric disordersc, % (SE)

6.1% (0.23)

2.5% (0.03)

Smoking, % (SE)

1.1% (0.18)

1.2% (0.03)

0.622

Obesity, % (SE)

8.1% (0.22)

9.6% (0.01)

0.162

Table 1.  Baseline characteristics of pregnant cancers survivors and pregnant women without cancers,
n = 18,751,723. a Care provided as charity, courtesy, or free of charge. b This category includes Worker’s
Compensation, the Civilian Health and Medical Program of the Uniformed Services, the Civilian Health and
Medical Program of the Department of Veterans Affairs, Title V, and other government programs. c Includes
anxiety, adjustment, eating, mood, personality, and psychotic disorders.

Results

The NIS sample included for this study had 3,814,715 weighted delivery-related hospitalizations, of which 13,109
women were cancer survivors, while 3,801,606 did not have a concomitant or previous cancer diagnosis. Using
appropriate sample weights for determining national estimates for the entire US population, we found that
there were 64,506 pregnant cancer survivors and 18,687,217 pregnant women without cancer. We reported only
weighted results because they were more meaningful and there were no significant changes due to inclusion of
sample weights.

Patient characteristics. The mean age of delivery was 30.5 years for women who were cancer survivors

and 28.0 years for women without cancer (Table 1). Pregnant cancer survivors were more likely to be white
patients (63.5% versus 52.9%) and less likely to be black (12.3% versus 14.5%), Hispanic (16.2% versus 21.6%),
Asian or Pacific Islander (4.1% versus 5.4%), or Native American patients (0.45% versus 0.80%). Pregnant cancer
survivors were more likely to be Medicare (1.8% versus 0.7%) and private insurance beneficiaries (57.5% versus
49.8%) and less likely to be Medicaid beneficiaries (35.9% versus 43.9%). Pregnant cancer survivors were more
likely to have multiple births (2.8% versus 1.8%), previous cesarean Sects. (18.9% versus 17.2%), pre-existing
diabetes (1.6% versus 1.0%), chronic renal disease (0.60% versus 0.28%), pre-existing hypertension (4.0% versus 2.3%), depression (4.8% versus 2.3%), alcohol or substance abuse (3.2% versus 1.8%), psychiatric disorders
(6.1% versus 2.5%), and higher Elixhauser comorbidity index (3.1% versus 0.70%). There were no significant
differences in smoking or obesity between the two groups.

Scientific Reports |

(2022) 12:9989 |

https://doi.org/10.1038/s41598-022-13852-4

3
Vol.:(0123456789)

www.nature.com/scientificreports/

Characteristics

Cancer Survivors

Without Cancer

20.1% (0.98)

16% (0.41)

Region, % (SE)

P value
< 0.001

Northeast
Midwest

21.2% (0.83)

21.2% (0.47)

South

35.9% (1.18)

38.1% (0.7)

West

22.8% (0.86)

24.7% (0.63)

Rural

7.8% (0.68)

11.4% (0.48)

Urban

92.2% (0.68)

88.6% (0.48)

11.7% (0.59)

12.4% (0.32)

Location, % (SE)

< 0.001

Bed sizea, % (SE)

< 0.001

Small
Medium

24.8% (0.91)

28.2% (0.58)

Large

63.5% (1.04)

59.4% (0.64)

Teaching

58.8% (2.2)

47.1% (1.39)

Non-teaching

41.2% (2.2)

52.9% (1.39)

Teaching status, % (SE)

< 0.001

Table 2.  Characteristics of Hospitals where Pregnant Cancers Survivors and Pregnant Women without
Cancers were Hospitalized for Delivery, n = 18,751,723. a Bed size categories are based on hospital beds and
are specific to the hospital’s location and teaching status. For details of categorization, please see: https://www.
hcup-us.ahrq.gov/db/vars/hosp_bedsize/nisnote.jsp.

Cancer types

% (SE)

Stomach

0.18% (0.04)

Colon

0.93% (0.08)

Liver

0.24% (0.04)

GI organs and peritoneum

0.99% (0.12)

Lung and bronchus

0.5% (0.06)

Breast

9.2% (0.28)

Uterus

0.42% (0.05)

Ovary

2.4% (0.14)

Other female genital organs

27.2% (0.98)

Melanomas of skin

1.8% (0.12)

Urinary

15.5% (0.39)

Lymphomas and leukemia

31.3% (0.62)

Cancer with unspecified primary

8.4% (0.43)

Secondary malignancies

0.94% (0.08)

Malignant neoplasm without specification of site

0.09% (0.03)

Table 3.  Cancer types and frequencies among pregnant cancer survivors, n = 64,506.

Hospital characteristics. There were differences in hospital characteristics such as region, location, bed
size, and teaching status between pregnant cancer survivors and those without cancer (Table 2). Pregnant cancer
survivors were more likely to be admitted to hospitals in Northeast region (20.1%), urban locations (92.2%),
teaching (58.8%), and large (63.5%) hospitals.
Cancer types. The most common cancers recorded in pregnant cancer survivors were lymphomas and leukemias (31.28%), female genital organ cancers (27.2%), urinary cancers (15.52%), and breast cancer (9.17%;
Table 3).

Maternal mortality. There were 58 maternal deaths per 100,000 pregnancies among cancer survivors, compared to 5 per 100,000 pregnancies among those without cancer. The odds of maternal mortality were almost 7
times higher among cancer survivors compared to those without cancer, after controlling for maternal age, race,
median household income for patient’s ZIP Code, insurance type, comorbidity index, hospital region, hospital
location, hospital teaching status, and survey years (adjusted OR [aOR], 6.90 [95% CI 2.07–23.0]; Table 4).
Obstetrical outcomes. Pregnant cancer survivors had significantly higher odds for adverse maternal morbidity outcomes as estimated by the severe maternal morbidity indicator (aOR 2.00 [95% CI 1.66–2.41]), when
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Women, No. (SE)
Outcome

Cancer survivors

Without cancer

Maternal death, % (SE)

0.06% (0.02)

0.005% (0.004)

Severe maternal morbidity, % (SE)

3.5% (0.17)

1.7% (0.02)

P value

Maternal outcome
0.010
< 0.001

Cesarean delivery, % (SE)

38.5% (0.49)

33.1% (0.12)

< 0.001

Induction of labor, % (SE)

22.3% (0.41)

19.2% (0.15)

< 0.001

Length of stay, mean (SE)
Cesarean delivery

4.3 (0.09)

3.5 (0.01)

< 0.001

Vaginal delivery

2.4 (0.03)

2.2 (0.01)

< 0.001

Length of stay > 6 days, % (SE)
Cesarean delivery

6.9% (0.38)

3.14% (0.05)

Vaginal delivery

1.3% (0.13)

0.66% (0.02)

Retained placenta, % (SE)

0.63% (0.07)

0.50% (0.01)

Gestational hypertension, % (SE)

4.3% (0.18)

4.2% (0.03)

Pre-eclampsia, % (SE)

5.8% (0.21)

4.4% (0.03)

Eclampsia, % (SE)

0.84% (0.03)

0.06% (0.001)

Antepartum hemorrhage, % (SE)

1.9% (0.12)

1.5% (0.01)

0.006

Postpartum hemorrhage, % (SE)

4.3% (0.2)

3.0% (0.04)

< 0.001

< 0.001
0.525

Gestational diabetes, % (SE)

8.1% (0.24)

6.5% (0.05)

< 0.001

Preterm labor, % (SE)

9.1% (0.29)

6.6% (0.05)

< 0.001

Premature rupture of membranes, % (SE)

5.5% (0.23)

4.3% (0.06)

< 0.001

Chorioamnionitis, % (SE)

2.4% (0.15)

1.9% (0.04)

< 0.001

Postpartum infection, % (SE)

0.84% (0.08)

0.67% (0.02)

Venous thromboembolism, % (SE)

1.0% (0.09)

0.21% (0.003)

< 0.001
< 0.001

Fetal outcome
Poor fetal growth, % (SE)

3.2% (0.16)

2.6% (0.03)

Excessive fetal growth, % (SE)

3.1% (0.16)

2.6% (0.03)

Fetal distress, % (SE)

16.7% (0.38)

14.6% (0.14)

Fetal central nervous system malformations, % (SE)

0.09% (0.02)

0.06% (0.002)

0.212

Fetal chromosomal abnormalities, % (SE)

0.16% (0.03)

0.09% (0.002)

< 0.001

Suspected fetal damage due to drugs or radiation, % (SE)

0.03% (0.01)

0.03% (0.001)

Decreased fetal movements, % (SE)

1.2% (0.11)

0.72% (0.01)

< 0.001

Stillbirth, % (SE)

0.47% (0.06)

0.62% (0.01)

0.120

0.002
< 0.001

0.903

Table 4.  Obstetrical outcomes among pregnant cancers survivors and pregnant women without cancers,
n = 18,751,723.

compared to those without cancer (Table 5). Pregnant cancer survivors also had significantly higher odds for
cesarean sections (aOR 1.27 [95% CI 1.19–1.37]) and labor inductions (aOR 1.17 [95% CI 1.07–1.29]). Hospital length of stay > 6 days was significantly higher among pregnant cancer survivors for both cesarean sections
(aOR 1.93 [95% CI 1.54–2.40]) and vaginal deliveries (aOR 2.17 [95% CI 1.56–3.04]). Mean hospital length of
stay was also higher among pregnant cancer survivors. The mean hospital length of stay for cesarean section
and vaginal delivery were 4.3 and 2.4 days, respectively, among pregnant cancer survivors compared to 3.5 and
2.2 days, respectively, among those without cancer. Pregnant cancer survivors had significantly higher odds for
pre-eclampsia (aOR 1.18 [95% CI 1.02–1.36]), preterm labor (aOR 1.55 [95% CI 1.36–1.76]), chorioamnionitis
(aOR 1.45 [95% CI 1.15–1.82]), postpartum infection (aOR 1.68 [95% CI 1.21–2.33]), and venous thromboembolism (aOR 3.62 [95% CI 2.69–4.88]).
Pregnant cancer survivors also had significantly higher odds for developing decreased fetal movements
(adjusted OR, 1.67 [95% CI 1.13–2.46]). However, no association was found between maternal cancer and other
fetal outcomes (Table 5).

Discussion

This study showed that the odds for maternal and fetal adverse outcomes were significantly higher among pregnant cancer survivors, compared to pregnant women without cancer, or a history of cancer. The most remarkable
finding included a 7-times higher odds for maternal mortality among cancer survivors. These women also had
higher levels of maternal morbidity, and complications such as pre-eclampsia, preterm labor, chorioamnionitis, postpartum infections, and venous thromboembolism compared to those without cancer. Pregnant cancer
survivors also had longer hospital length of stay and were more likely to undergo cesarean section and labor
inductions. Pregnant cancer survivors also had greater odds for decreased fetal movements compared to those
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Outcome

Crude OR (95% CI)

Adjusted OR (95% CI)a

Maternal outcome
Maternal death

11.05 (5.46–22.34)

6.90 (2.07–22.98)

Severe maternal morbidity

2.06 (1.87–2.27)

2.00 (1.66–2.41)

Cesarean delivery

1.26 (1.22–1.32)

1.27 (1.19–1.37)

Labor induction

1.21 (1.16–1.27)

1.17 (1.07–1.29)

Length of stay > 6 days
Cesarean delivery

2.29 (2.05–2.56)

1.93 (1.54–2.40)

Vaginal delivery

1.99 (1.63–2.42)

2.17 (1.56–3.04)

Retained placenta

1.06 (0.71–1.58)

Gestational hypertension

0.91 (0.77–1.09)
1.18 (1.02–1.36)

Pre-eclampsia
Eclampsia

1.23 (0.69–2.24)

0.92 (0.23–3.74)

Antepartum hemorrhage

1.22 (1.08–1.39)

1.04 (0.81–1.35)

Postpartum hemorrhage

1.44 (1.31–1.57)

1.16 (0.91–1.42)

Gestational diabetes

1.27 (1.20–1.36)

0.99 (0.87–1.14)

Preterm labor

1.41 (1.32–1.50)

1.55 (1.36–1.76)

Premature rupture of membranes

1.29 (1.19–1.40)

1.06 (0.92–1.23)

Chorioamnionitis

1.27 (1.28–1.43)

1.45 (1.15–1.82)

4.89 (4.12–5.79)

3.62 (2.69–4.88)

1.68 (1.21–2.33)

Postpartum infection
Venous thromboembolism
Fetal outcome
Poor fetal growth

1.27 (1.15–1.40)

1.20 (0.97–1.48)

Excessive fetal growth

1.20 (1.08–1.32)

1.09 (0.89–1.33)

Fetal distress

1.17 (1.12–1.23)

1.07 (0.97–1.18)

Fetal central nervous system malformations

1.56 (0.89–2.72)

1.32 (0.44–3.97)

Fetal chromosomal abnormalities

1.83 (1.18–2.83)

0.83 (0.26–2.62)

Suspected fetal damage due to drugs or radiation

1.07 (1.40–2.82)

0.91 (0.13–6.32)

Decreased fetal movements

1.72 (1.45–2.05)

1.67 (1.13–2.46)

Stillbirth

0.76 (0.58–1.00)

0.90 (0.56–1.44)

Table 5.  Predictors of obstetrical outcomes among pregnant cancers survivors and pregnant women without
cancers, n = 18,751,723. a Adjusted for maternal age, race, quartile of median household income for patient’s
zip code, Elixhauser comorbidity index, hospital region, hospital location, hospital teaching status and year.
Significant values are in bold.

without cancer, though stillbirth was not affected. In accordance with the higher odds for maternal and fetal
adverse outcomes observed in our study, we also found that pregnant cancer survivors were more likely to be
admitted to larger, urban, and teaching hospitals with better treatment options. Similar to our findings, Terry et al.
found that pregnant women with CNS neoplasms were more likely to be admitted to larger teaching hospitals24.
Although pregnant cancer survivors had a 7-times higher odds for maternal mortality (59 versus 5 deaths
per 100,000 pregnancies), this may underestimate maternal mortality because only deaths that occurred during delivery hospitalizations were included, and data on peripartum and postpartum deaths were not available.
However, despite the several fold increase in maternal mortality found in our study, it should be noted that
absolute maternal mortality during delivery is still very uncommon among cancer survivors. The risk difference
in maternal mortality between pregnant cancer survivors and pregnant women without cancer was 0.01 (95%
CI 0.006–0.014).
We could not infer the specific cause for increased mortality during delivery hospitalizations among pregnant
cancer survivors. Putatively, the increased odds could be due to cancer, or higher severe maternal morbidity
indicators, or due to higher rates of obstetric life-threatening complications such as chorioamnionitis and venous
thromboembolism. In order to estimate the effect of these life-threatening conditions on mortality, we included
these factors in equations for maternal mortality in addition to other covariates. However, our results did not
change significantly, and maternal mortality remained the same. Hence, we could not ascertain which of these
life-threatening conditions significantly affected maternal mortality. Although we could not define the specific
causes underlying the higher rates of maternal mortality from the available data, it is certain that pregnant cancer survivors have higher odds for morbidity and mortality and need additional c are25,26. Future studies should
focus on ascertaining the specific causes of higher rates of mortality in this population for developing effective
interventions.
Though the majority of the outcomes in our study were also reported in previous studies among pregnant
cancer survivors, we could calculate more generalizable estimates because of the nationally representative large
database used for this study. Similar to studies among pregnant women with cancers, our study also showed
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increased odds for pre-eclampsia, chorioamnionitis, venous thromboembolism, preterm labor, cesarean section,
labor induction, and increased length of stay12–16,27. We found that pregnant cancer survivors had 38% higher
odds for cesarean section, accounting for approximately 3700 additional cesarean sections per 100,000 deliveries,
and 22% higher odds for labor induction, translating to 3100 additional labor inductions per 100,000 deliveries.
This could be due to the fact that cesarean section and labor induction may be recommended for reasons such
as early initiation of chemotherapy or other cancer treatments. Similarly, estimated odds for other conditions
accounted for 510 additional cases of chorioamnionitis, 810 additional cases of venous thromboembolism, and
2400 additional cases of preterm labor per 100,000 deliveries among pregnant cancer survivors. However, our
study did not show any increased odds for antepartum hemorrhage, postpartum hemorrhage, and premature
rupture of m
 embrane12,13,15. Contrary to findings in a previous s tudy12, our study did not show increased odds
for gestational diabetes among pregnant cancer survivors.
Our study showed that 1.2% of pregnant cancer survivors had decreased fetal movements, compared to 0.72%
among pregnant women without cancers. However, we did not find an increased odds for adverse fetal outcomes,
such as abnormal fetal growth, fetal distress, and fetal malformations as reported in other studies done among
pregnant women with c ancer12,28. Although cancer could be associated with adverse fetal outcomes, the absence
of such associations in this cohort could be due to significant improvements in pre- and perinatal screening
and appropriate management. Nevertheless, the relationship between cancer treatments and decreased fetal
movements should be explored in greater details in future studies. There could be several reasons for increased
maternal mortality and complications among cancer survivors in our study. Chemotherapy and radiotherapy
could adversely affect reproductive organs such as uterus and ovaries and produce permanent mutations in ovum
leading to adverse delivery outcomes29. In addition, cancers of reproductive organs could result in anatomical
changes to organs like the uterus leading to spontaneous abortions and other obstetric complications30.

Strengths and limitations. One of the main strengths of this study was that it was one of the few large-

scale studies that evaluated maternal and fetal outcomes among pregnant women with cancer at the national
level. Pregnancy among cancer survivors is rare and estimating outcomes such as maternal mortality and pregnancy related complications require large sample sizes. NIS is the largest all payer inpatient database in the US
and contains data from approximately 19 million weighted delivery hospitalizations and 64,000 delivered cancer
survivors. This large database was helpful in estimating such rare outcomes. Because of the complex survey
design, NIS represents discharges from all community hospitals within the US, thereby providing a precise estimate of maternal and fetal outcomes among pregnant women with cancers in the US.
In spite of these strengths, our study has some limitations. We used ICD-9 codes for identifying delivery
hospitalizations, associated conditions, and procedures. There could be some potential coding errors and missing
codes leading to misclassification bias. NIS does not record readmission and considers it as independent new
admission. In addition, the unit of measurement in NIS is hospitalization and not the patient. This could have
obscured the distinction between index admission and readmission. NIS lacks many cancer-related details, such
as year since diagnosis, cancer staging, treatment and whether cancer was diagnosed before or during pregnancy
or during childhood, or pregnancy-related details, such as use of assisted reproductive technologies. In addition,
we were unable to distinguish between cancer during pregnancy, at delivery, and pre-pregnancy. This limits our
understanding about the effects of these factors on maternal and fetal outcomes during delivery hospitalizations.
Cancer history could be more likely to be coded during the hospitalization in the presence of an adverse pregnancy outcome, leading to differential reporting bias. The association between maternal and neonatal outcomes
could not be ascertained because NIS deidentifies data and maternal and neonatal records could not be linked
together, and hence, neonatal complications due to cancer among mothers could not be tracked and estimated.
In addition, women who have previously experienced adverse pregnancy or birth outcomes have greater risks
in successive pregnancies. However, this could not be ascertained because successive pregnancies by the same
woman could not be identified. Many conditions that were not directly associated with maternal and fetal outcomes may not have been recorded in discharge data leading to differential reporting biases and imprecisions
in estimating odds r atios31,32. Many pre-existing chronic diseases may not be recorded because of lack of direct
association with obstetric or neonatal care, leading to imprecise estimation of their prevalence. Additionally,
this imprecision in estimating chronic conditions may have differentially affected data from pregnant cancer
survivors compared to pregnant women without cancer because cancer survivors could have received greater
levels of monitoring and care before as well as during pregnancy and during delivery hospitalizations as well.
We have only included NIS data collected during 2010 to 2014 because ICD-9 codes were used until 2014 and
subsequently ICD-10 codes from 2015 onwards. To avoid misclassification bias due to this change we restricted
our period of analysis.

Conclusion

Though pregnancy is rare among cancer survivors, approximately 400,000 women in the reproductive-age group
have history of cancer and could become p
 regnant33. Thus, there is vital need to understand this risk and prevent
adverse maternal and fetal outcomes in this population. Because of significantly higher maternal and fetal adverse
outcomes among pregnant cancer survivors, it is evident that pregnancy in this group constitutes a high-risk condition and requires advanced care from many subspecialties such as oncology, obstetrics, pediatrics, and critical
care. Though referrals to Level 4 hospitals have significantly improved maternal outcomes for many obstetrical
complications34, whether similar referrals could improve outcomes in women with cancer is yet to be understood.
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